NASDAQ:CRIS - Nasdaq - US2312693094 - Common Stock - Currency: USD
NASDAQ:CRIS (2/21/2025, 8:10:54 PM)
3.1
0 (0%)
The current stock price of CRIS is 3.1 USD. In the past month the price decreased by -9.62%. In the past year, price decreased by -67.4%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. The company is headquartered in Lexington, Massachusetts and currently employs 48 full-time employees. The company went IPO on 2000-08-01. The firm is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
CURIS INC
128 Spring Street, Building C, Suite 500
Lexington MASSACHUSETTS 02421 US
CEO: James Dentzer
Employees: 49
Company Website: https://www.curis.com/
Investor Relations: http://investors.curis.com/
Phone: 16175036500
The current stock price of CRIS is 3.1 USD.
The exchange symbol of CURIS INC is CRIS and it is listed on the Nasdaq exchange.
CRIS stock is listed on the Nasdaq exchange.
12 analysts have analysed CRIS and the average price target is 21.42 USD. This implies a price increase of 590.97% is expected in the next year compared to the current price of 3.1. Check the CURIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CURIS INC (CRIS) has a market capitalization of 26.26M USD. This makes CRIS a Nano Cap stock.
CURIS INC (CRIS) currently has 49 employees.
CURIS INC (CRIS) has a support level at 3.07 and a resistance level at 3.37. Check the full technical report for a detailed analysis of CRIS support and resistance levels.
The Revenue of CURIS INC (CRIS) is expected to decline by -6.38% in the next year. Check the estimates tab for more information on the CRIS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CRIS does not pay a dividend.
CURIS INC (CRIS) will report earnings on 2025-05-05, before the market open.
CURIS INC (CRIS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-7.81).
The outstanding short interest for CURIS INC (CRIS) is 2.11% of its float. Check the ownership tab for more information on the CRIS short interest.
ChartMill assigns a fundamental rating of 1 / 10 to CRIS. CRIS has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months CRIS reported a non-GAAP Earnings per Share(EPS) of -7.81. The EPS increased by 16.29% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -107.09% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 80% to CRIS. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of 21% and a revenue growth -6.38% for CRIS